Abstract
It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Keywords: IFN, ISGs, HCV, IL-28B, IFNL4, DAAs, innate immunity.
Graphical Abstract
Current Drug Targets
Title:Role of Interferons in Chronic Hepatitis C Infection
Volume: 18 Issue: 7
Author(s): Carolina Scagnolari, Katia Monteleone, Giulia Cacciotti and Guido Antonelli*
Affiliation:
- Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Viale di Porta Tiburtina 28 – 00185 Rome,Italy
Keywords: IFN, ISGs, HCV, IL-28B, IFNL4, DAAs, innate immunity.
Abstract: It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Export Options
About this article
Cite this article as:
Scagnolari Carolina, Monteleone Katia, Cacciotti Giulia and Antonelli Guido*, Role of Interferons in Chronic Hepatitis C Infection, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450117666160201112632
DOI https://dx.doi.org/10.2174/1389450117666160201112632 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Effect of Some Triterpene Glycosides Applied in vitro on Chromatin State in Human Cells
Current Bioactive Compounds Expansion or Depletion of T Follicular Helper Cells During HIV Infection: Consequences for B cell Responses
Current HIV Research High-Level Secretory Expression and Purification of Recombinant Human Interleukin 1 Beta in Pichia pastoris
Protein & Peptide Letters Oxaliplatin-Induced Lung Toxicity. Case Report and Review of the Literature
Current Drug Safety Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Finding Relevant Genes Involved in the Cytotoxicity Mechanisms of Anticancer Biophores
Current Computer-Aided Drug Design The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance
Current Medicinal Chemistry Editorial
Current Pediatric Reviews Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews About the Guest Editors
Recent Patents on Inflammation & Allergy Drug Discovery Analytical Features of Diclofenac Evaluation in Water as a Potential Marker of Anthropogenic Pollution
Current Pharmaceutical Analysis The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy
Current Molecular Pharmacology Structural Features of Angiotensin-I Converting Enzyme Catalytic Sites: Conformational Studies in Solution, Homology Models and Comparison with Other Zinc Metallopeptidases
Current Topics in Medicinal Chemistry